Myriad (MYGN) Reports Q1 Earnings: What Key Metrics Have to Say

For the quarter ended March 2024, Myriad Genetics (MYGN) reported revenue of $202.2 million, up 11.6% over the same period last year. EPS came in at -$ 0.01, compared to - $0.21 in the year-ago quarter.The reported revenue represents a surprise of +4.55% over the Zacks Consensus Estimate of$ 193.4 million. With the consensus EPS estimate being -$0.11, the EPS surprise was +90.91%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall St ...